grapiprant + grapiprant and pembrolizumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microsatellite Stable Colorectal Cancer
Conditions
Microsatellite Stable Colorectal Cancer
Trial Timeline
Sep 20, 2018 → Mar 7, 2023
NCT ID
NCT03658772About grapiprant + grapiprant and pembrolizumab
grapiprant + grapiprant and pembrolizumab is a phase 1 stage product being developed by Merck for Microsatellite Stable Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03658772. Target conditions include Microsatellite Stable Colorectal Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03658772 | Phase 1 | Completed |
Competing Products
11 competing products in Microsatellite Stable Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| MK-3475 + INCB024360 | Merck | Phase 1/2 | 41 |
| AMG 436 | Amgen | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Copanlisib + Nivolumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016 | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| Balstilimab + Botensilimab | Agenus | Phase 2 | 44 |